# Iressa v BSC (Best Supportive Care) in First Line NSCLC

> **NCT00259064** · PHASE2,PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 216 (actual)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** Gefitinib
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00259064
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** 2007-02
- **Final completion:** 2016-04
- **Target enrollment:** 216 (ACTUAL)
- **Last updated:** 2016-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00259064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00259064, "Iressa v BSC (Best Supportive Care) in First Line NSCLC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00259064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*